Prescription Drug Transparency and Affordability Act
Bipartisan House Bill Targets Pharmacy Middlemen to Reveal Secret Drug Rebates and Costs
This bill is currently in the early stages of the legislative process and is being reviewed by three different House committees. It is actively moving forward as it waits for these committees to finish their work. There are no upcoming votes scheduled at this time.
Legislative Progress
There is strong bipartisan interest in lowering drug costs by regulating middlemen. However, similar bills often face heavy lobbying from the insurance industry which can slow them down.
Key Points
Impact Analysis
Personal Impact
Life & Work
Small business owners who sponsor group health plans will receive summary reports from PBMs showing estimated net prices, cost per claim, fee structures, and cost per participant. This gives smaller employers better information to shop for PBM services and negotiate better deals. Employers with 100+ employees get even more detailed drug-level data. The transparency could help businesses that currently lack bargaining power against large PBMs.
Programs
Disabilities
Milestones
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
4 articlesPBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency
President Trump signed a spending bill into law that includes major PBM reforms aimed at increasing price transparency. The policy requires PBMs to receive flat administrative fees and pass through 100% of rebates, fees, and other remuneration to the payer, reducing incentives for high drug prices.
McDonald Rivet introduces bill to increase transparency for prescription drug prices
Rep. Kristen McDonald Rivet introduced the Prescription Drug Transparency and Affordability Act to increase oversight of Pharmacy Benefit Managers. The bill mandates disclosure of financial transactions and imposes penalties of up to $100,000 for providing false information.
PBM Reform Takes Off in 2025
The year 2025 is seeing a surge in PBM reform efforts at both the state and federal levels. New legislation aims to prohibit spread pricing and require PBMs to report on the rebates they receive, ensuring that savings are passed on to patients and employers.
Source Information
Document Type
Congressional Bill
Official Title
Prescription Drug Transparency and Affordability Act
Data Sources
Sponsor
Cosponsors
(3)Analysis generated by AI. Always verify with official sources.